Exploring a Suitable Marker of Glycemic Response to Dulaglutide in Patients with Type 2 Diabetes: A Retrospective Study

Introduction Previous studies suggested that β-cell function markers such as fasting and postprandial serum C-peptide and C-peptide increment (FCPR, PCPR, and ΔCPR, respectively) may be useful in estimating glycemic response to glucagon-like peptide-1 receptor agonists. However, it remains elusive w...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes therapy 2022-04, Vol.13 (4), p.733-746
Main Authors: Yoshiji, Satoshi, Hasebe, Masashi, Iwasaki, Yorihiro, Shibue, Kimitaka, Keidai, Yamato, Seno, Yohei, Iwasaki, Kanako, Honjo, Sachiko, Fujikawa, Jun, Hamasaki, Akihiro
Format: Article
Language:English
Subjects:
Cardiology
Care and treatment
Diabetes
Endocrinology
Generalized linear models
GLP-1 receptor agonists
Glycosylated hemoglobin
Health aspects
Internal Medicine
Medicine
Medicine & Public Health
Original Research
Patient outcomes
Peptides
Type 2 diabetes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction Previous studies suggested that β-cell function markers such as fasting and postprandial serum C-peptide and C-peptide increment (FCPR, PCPR, and ΔCPR, respectively) may be useful in estimating glycemic response to glucagon-like peptide-1 receptor agonists. However, it remains elusive whether baseline glycemic control confounds these markers. Here we aimed to identify the least confounded β-cell function markers and investigate whether these markers could predict glycemic response to dulaglutide. Methods We evaluated FCPR, PCPR, and ΔCPR levels in patients with type 2 diabetes who initiated dulaglutide treatment after a standardized meal tolerance test (MTT). We first investigated the confounding effects of baseline HbA1c on β-cell function markers using Pearson’s correlation test. Then, we evaluated the association between each β-cell function marker and glycemic response (HbA1c change 0–6 months) to dulaglutide using generalized linear model and logistic regression analysis with adjustment for baseline HbA1c. Results In 141 patients, baseline HbA1c was significantly inversely correlated with PCPR and ΔCPR ( P  
ISSN:1869-6953
1869-6961
DOI:10.1007/s13300-022-01231-1